D.E. Shaw & Co
FHTX icon

D.E. Shaw & Co’s Foghorn Therapeutics FHTX Stock Holding History

D.E. Shaw & Co’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,875
Closed -$54.3K – 4457
2025
Q1 		$54.3K Sell
14,875
-85,492
-85% -$390K ﹤0.01% 4059
2024
Q4 		$474K Buy
100,367
+30,671
+44% +$223K ﹤0.01% 3654
2024
Q3 		$649K Buy
69,696
+43,958
+171% +$318K ﹤0.01% 3556
2024
Q2 		$148K Buy
+25,738
New +$153K ﹤0.01% 4125
2022
Q2 		– Sell
-19,855
Closed -$302K – 5456
2022
Q1 		$302K Buy
19,855
+5,687
+40% +$78K ﹤0.01% 4645
2021
Q4 		$324K Buy
+14,168
New +$204K ﹤0.01% 4644

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

D.E. Shaw & Co's FHTX Position: Q2 2025 in Review

D.E. Shaw & Co sold out of Foghorn Therapeutics (FHTX) in Q2 2025, closing a stake of 14,875 shares — an estimated $54.3K sold.

D.E. Shaw & Co first reported a position in FHTX in Q4 2021 and held it in 6 quarters. The position peaked at $649K in Q3 2024. 81 funds tracked by Wall St. Rank hold FHTX as of Q2 2025.

  • D.E. Shaw & Co reported no remaining Foghorn Therapeutics position as of Q2 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 14,875 Foghorn Therapeutics shares in Q2 2025, an estimated $54.3K.
  • D.E. Shaw & Co first reported a position in Foghorn Therapeutics in Q4 2021 and held it in 6 quarters.
  • D.E. Shaw & Co's Foghorn Therapeutics position peaked at $649K in Q3 2024.
  • 81 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.